{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:22:09Z","timestamp":1777512129833,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["2019-AARG-644347"],"award-info":[{"award-number":["2019-AARG-644347"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/145979\/2019 (Ph.D. scholarship)"],"award-info":[{"award-number":["SFRH\/BD\/145979\/2019 (Ph.D. scholarship)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Exosomes are small extracellular vesicles (EVs) present in human biofluids that can transport specific disease-associated molecules. Consequently blood-derived exosomes have emerged as important peripheral biomarker sources for a wide range of diseases, among them Alzheimer\u2019s disease (AD). Although there is no effective cure for AD, an accurate diagnosis, relying on easily accessible peripheral biofluids, is still necessary to discriminate this disease from other dementias, test potential therapies and even monitor rate of disease progression. The ultimate goal is to produce a cost-effective and widely available alternative, which can also be employed as a first clinical screen. In this study, EVs with exosome-like characteristics were isolated from serum of Controls and AD cases through precipitation- and column-based methods, followed by mass spectrometry analysis. The resulting proteomes were characterized by Gene Ontology (GO) and multivariate analyses. Although GO terms were similar for exosomes\u2019 proteomes of Controls and ADs, using both methodologies, a clear segregation of disease cases was obtained when using the precipitation-based method. Nine significantly different abundant proteins were identified between Controls and AD cases, representing putative biomarker candidate targets. Among them are AACT and C4BP\u03b1, two A\u03b2-binding proteins, whose exosome levels were further validated in individuals from independent cohorts using antibody-based approaches. The findings discussed represent an important contribution to the identification of novel exosomal biomarker candidates useful as potential blood-based tools for AD diagnosis.<\/jats:p>","DOI":"10.1007\/s12035-022-02762-1","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T09:02:37Z","timestamp":1645779757000},"page":"2838-2854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Novel Exosome Biomarker Candidates for Alzheimer\u2019s Disease Unravelled Through Mass Spectrometry Analysis"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3017-2092","authenticated-orcid":false,"given":"T\u00e2nia","family":"Soares Martins","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0699-335X","authenticated-orcid":false,"given":"Rui","family":"Mar\u00e7alo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1231-3819","authenticated-orcid":false,"given":"Crist\u00f3v\u00e3o B.","family":"da Cruz e Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8536-4609","authenticated-orcid":false,"given":"D\u00e1rio","family":"Trindade","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-5702","authenticated-orcid":false,"given":"Jos\u00e9","family":"Catita","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-1749","authenticated-orcid":false,"given":"Francisco","family":"Amado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0508-4034","authenticated-orcid":false,"given":"T\u00e2nia","family":"Melo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6536-8728","authenticated-orcid":false,"given":"Ilka Martins","family":"Rosa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-8193","authenticated-orcid":false,"given":"Jonathan","family":"Vogelgsang","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-5330","authenticated-orcid":false,"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3718-9874","authenticated-orcid":false,"given":"Odete A. B.","family":"da Cruz e Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-6979","authenticated-orcid":false,"given":"Ana Gabriela","family":"Henriques","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"2762_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14:32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5","journal-title":"Mol Neurodegener"},{"key":"2762_CR2","doi-asserted-by":"publisher","unstructured":"Henriques AG, M\u00fcller T, Oliveira JM, Cova M, da Cruz e Silva CB, da Cruz e Silva OAB (2016) Altered protein phosphorylation as a resource for potential AD biomarkers. Sci Rep 6:30319. https:\/\/doi.org\/10.1038\/srep30319","DOI":"10.1038\/srep30319"},{"key":"2762_CR3","doi-asserted-by":"publisher","unstructured":"Henriques AG, Oliveira JM, Carvalho LP, da Cruz e Silva OAB (2015) A\u03b2 influences cytoskeletal signaling cascades with consequences to Alzheimer\u2019s disease. Mol Neurobiol 52, 1391\u20131407. https:\/\/doi.org\/10.1007\/s12035-014-8913-4","DOI":"10.1007\/s12035-014-8913-4"},{"key":"2762_CR4","doi-asserted-by":"publisher","unstructured":"Oliveira J, Costa M, de Almeida MSC, da Cruz e Silva OAB, Henriques AG (2017) Protein phosphorylation is a key mechanism in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 58:953\u201378. https:\/\/doi.org\/10.3233\/JAD-170176","DOI":"10.3233\/JAD-170176"},{"key":"2762_CR5","doi-asserted-by":"publisher","unstructured":"Domingues C, da Cruz e Silva OAB, Henriques AG (2017) Impact of cytokines and chemokines on Alzheimer\u2019s disease neuropathological hallmarks. Curr Alzheimer Res 14:870\u201382. https:\/\/doi.org\/10.2174\/1567205014666170317113606","DOI":"10.2174\/1567205014666170317113606"},{"key":"2762_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3233\/JAD-2009-1177","volume":"18","author":"K Blennow","year":"2009","unstructured":"Blennow K, Zetterberg H (2009) Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease. J Alzheimers Dis 18:413\u2013417. https:\/\/doi.org\/10.3233\/JAD-2009-1177","journal-title":"J Alzheimers Dis"},{"key":"2762_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00702-008-0177-6","volume":"116","author":"V Welge","year":"2009","unstructured":"Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki H-W et al (2009) Combined CSF tau, p-tau181 and amyloid-\u03b2 38\/40\/42 for diagnosing Alzheimer\u2019s disease. J Neural Transm 116:203\u2013212. https:\/\/doi.org\/10.1007\/s00702-008-0177-6","journal-title":"J Neural Transm"},{"key":"2762_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, O\u2019Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S et al (2018) Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 14:639\u2013652. https:\/\/doi.org\/10.1038\/s41582-018-0079-7","journal-title":"Nat Rev Neurol"},{"key":"2762_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ceb.2014.05.004","volume":"29","author":"J Kowal","year":"2014","unstructured":"Kowal J, Tkach M, Th\u00e9ry C (2014) Biogenesis and secretion of exosomes. Curr Opin Cell Biol 29:116\u2013125. https:\/\/doi.org\/10.1016\/j.ceb.2014.05.004","journal-title":"Curr Opin Cell Biol"},{"key":"2762_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4132\/jptm.2017.05.21","volume":"52","author":"D Armstrong","year":"2018","unstructured":"Armstrong D, Wildman DE (2018) Extracellular vesicles and the promise of continuous liquid biopsies. J Pathol Transl Med 52:1\u20138. https:\/\/doi.org\/10.4132\/jptm.2017.05.21","journal-title":"J Pathol Transl Med"},{"key":"2762_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.bbadis.2015.09.020","volume":"1862","author":"KM Kanninen","year":"2016","unstructured":"Kanninen KM, Bister N, Koistinaho J, Malm T (2016) Exosomes as new diagnostic tools in CNS diseases. Biochim Biophys Acta 1862:403\u2013410. https:\/\/doi.org\/10.1016\/j.bbadis.2015.09.020","journal-title":"Biochim Biophys Acta"},{"key":"2762_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jnc.15112","volume":"156","author":"T Soares Martins","year":"2020","unstructured":"Soares Martins T, Trindade D, Vaz M, Campelo I, Almeida M, Trigo G et al (2020) Diagnostic and therapeutic potential of exosomes in Alzheimer\u2019s disease. J Neurochem 156:162\u2013181. https:\/\/doi.org\/10.1111\/jnc.15112","journal-title":"J Neurochem"},{"key":"2762_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","volume":"11","author":"MS Fiandaca","year":"2015","unstructured":"Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB et al (2015) Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement 11:600\u20137.e1. https:\/\/doi.org\/10.1016\/j.jalz.2014.06.008","journal-title":"Alzheimers Dement"},{"key":"2762_CR14","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1096\/fj.201600756R","volume":"30","author":"EJ Goetzl","year":"2016","unstructured":"Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach IV, Goetzl L et al (2016) Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer\u2019s disease. FASEB J 30:3853\u20133859. https:\/\/doi.org\/10.1096\/fj.201600756R","journal-title":"FASEB J"},{"key":"2762_CR15","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaneurol.2019.2462","volume":"76","author":"D Kapogiannis","year":"2019","unstructured":"Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD et al (2019) Association of extracellular vesicle biomarkers with Alzheimer disease in the Baltimore longitudinal study of aging. JAMA Neurol 76:1340\u20131351. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2462","journal-title":"JAMA Neurol"},{"key":"2762_CR16","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1096\/fj.201600816R","volume":"30","author":"EJ Goetzl","year":"2016","unstructured":"Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL et al (2016) Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease. FASEB J 30:4141\u20134148. https:\/\/doi.org\/10.1096\/fj.201600816R","journal-title":"FASEB J"},{"key":"2762_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/ana.25172","volume":"83","author":"EJ Goetzl","year":"2018","unstructured":"Goetzl EJ, Schwartz JB, Abner EL, Jicha GA, Kapogiannis D (2018) High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol 83:544\u2013552. https:\/\/doi.org\/10.1002\/ana.25172","journal-title":"Ann Neurol"},{"key":"2762_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.dadm.2018.11.002","volume":"11","author":"CN Winston","year":"2019","unstructured":"Winston CN, Goetzl EJ, Schwartz JB, Elahi FM, Rissman RA (2019) Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer\u2019s disease dementia. Alzheimers Dement (Amst) 11:61\u201366. https:\/\/doi.org\/10.1016\/j.dadm.2018.11.002","journal-title":"Alzheimers Dement (Amst)"},{"key":"2762_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dadm.2016.04.001","volume":"3","author":"CN Winston","year":"2016","unstructured":"Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D et al (2016) Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst) 3:63\u201372. https:\/\/doi.org\/10.1016\/j.dadm.2016.04.001","journal-title":"Alzheimers Dement (Amst)"},{"key":"2762_CR20","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/mp.2014.127","volume":"20","author":"L Cheng","year":"2015","unstructured":"Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A et al (2015) Prognostic serum miRNA biomarkers associated with Alzheimer\u2019s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry 20:1188\u20131196. https:\/\/doi.org\/10.1038\/mp.2014.127","journal-title":"Mol Psychiatry"},{"key":"2762_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139233","volume":"10","author":"G Lugli","year":"2015","unstructured":"Lugli G, Cohen AM, Bennett DA, Shah RC, Fields CJ, Hernandez AG et al (2015) Plasma exosomal miRNAs in persons with and without Alzheimer disease: altered expression and prospects for biomarkers. PLoS ONE 10:e0139233. https:\/\/doi.org\/10.1371\/journal.pone.0139233","journal-title":"PLoS ONE"},{"key":"2762_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3233\/JAD-191034","volume":"74","author":"T Soares Martins","year":"2020","unstructured":"Soares Martins T, Magalh\u00e3es S, Rosa IM, Vogelgsang J, Wiltfang J, Delgadillo I et al (2020) Potential of FTIR spectroscopy applied to exosomes for Alzheimer\u2019s disease discrimination: a pilot study. J Alzheimer\u2019s Dis 74:391\u2013405. https:\/\/doi.org\/10.3233\/JAD-191034","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2762_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12089","volume":"10","author":"H Su","year":"2021","unstructured":"Su H, Rustam YH, Masters CL, Makalic E, McLean CA, Hill AF et al (2021) Characterization of brain-derived extracellular vesicle lipids in Alzheimer\u2019s disease. J Extracell Vesicles 10:e12089. https:\/\/doi.org\/10.1002\/jev2.12089","journal-title":"J Extracell Vesicles"},{"key":"2762_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40120-019-00165-4","volume":"8","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Otto M (2019) A review on MS-based blood biomarkers for Alzheimer\u2019s disease. Neurol Ther 8:113\u2013127. https:\/\/doi.org\/10.1007\/s40120-019-00165-4","journal-title":"Neurol Ther"},{"key":"2762_CR25","doi-asserted-by":"publisher","unstructured":"Rosa IM, Henriques AG, Carvalho L, Oliveira J, da Cruz e Silva OAB (2017) Screening younger individuals in a primary care setting flags putative dementia cases and correlates gastrointestinal diseases with poor cognitive performance. Dement Geriatr Cogn Disord 43:15\u201328. https:\/\/doi.org\/10.1159\/000452485","DOI":"10.1159\/000452485"},{"key":"2762_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JAD-170501","volume":"61","author":"IM Rosa","year":"2018","unstructured":"Rosa IM, Henriques AG, Wiltfang J, da Cruz E, Silva OAB (2018) Putative dementia cases fluctuate as a function of mini-mental state examination cut-off points. J Alzheimers Dis 61:157\u2013167. https:\/\/doi.org\/10.3233\/JAD-170501","journal-title":"J Alzheimers Dis"},{"key":"2762_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13195-018-0448-x","volume":"10","author":"H Shahpasand-Kroner","year":"2018","unstructured":"Shahpasand-Kroner H, Klafki H-W, Bauer C, Schuchhardt J, H\u00fcttenrauch M, Stazi M et al (2018) A two-step immunoassay for the simultaneous assessment of A\u03b238, A\u03b240 and A\u03b242 in human blood plasma supports the A\u03b242\/A\u03b240 ratio as a promising biomarker candidate of Alzheimer\u2019s disease. Alzheimers Res Ther 10:121. https:\/\/doi.org\/10.1186\/s13195-018-0448-x","journal-title":"Alzheimers Res Ther"},{"key":"2762_CR28","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00221-018-5210-x","volume":"236","author":"J Vogelgsang","year":"2018","unstructured":"Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R, Streit F, Vukovich R, Wiltfang J (2018) Multiplex immunoassay measurement of amyloid-\u03b242 to amyloid-\u03b240 ratio in plasma discriminates between dementia due to Alzheimer\u2019s disease and dementia not due to Alzheimer\u2019s disease. Exp Brain Res 236:1241\u20131250. https:\/\/doi.org\/10.1007\/s00221-018-5210-x","journal-title":"Exp Brain Res"},{"key":"2762_CR29","doi-asserted-by":"publisher","unstructured":"Soares Martins T, Catita J, Martins Rosa I, da Cruz e Silva O.A.B., Henriques AG (2018) Exosome isolation from distinct biofluids using precipitation and column-based approaches. PLoS One 13:e0198820. https:\/\/doi.org\/10.1371\/journal.pone.0198820","DOI":"10.1371\/journal.pone.0198820"},{"key":"2762_CR30","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.3390\/ijms22083933","volume":"22","author":"T Soares Martins","year":"2021","unstructured":"Soares Martins T, Mar\u00e7alo R, Ferreira M, Vaz M, Silva RM, Rosa IM et al (2021) Exosomal A\u03b2-binding proteins identified by \u201cin silico\u201d analysis represent putative blood-derived biomarker candidates for alzheimer\u00b4s disease. Int J Mol Sci 22:3933. https:\/\/doi.org\/10.3390\/ijms22083933","journal-title":"Int J Mol Sci"},{"key":"2762_CR31","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/nprot.2006.468","volume":"1","author":"A Shevchenko","year":"2007","unstructured":"Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M (2007) In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1:2856\u20132860. https:\/\/doi.org\/10.1038\/nprot.2006.468","journal-title":"Nat Protoc"},{"key":"2762_CR32","doi-asserted-by":"publisher","unstructured":"Chong J, Wishart DS, Xia J (2019) Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinforma 68:e86. https:\/\/doi.org\/10.1002\/cpbi.86","DOI":"10.1002\/cpbi.86"},{"key":"2762_CR33","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1016\/j.molimm.2008.04.025","volume":"45","author":"LA Trouw","year":"2008","unstructured":"Trouw LA, Nielsen HM, Minthon L, Londos E, Landberg G, Veerhuis R et al (2008) C4b-binding protein in Alzheimer\u2019s disease: binding to Abeta1-42 and to dead cells. Mol Immunol 45:3649\u20133660. https:\/\/doi.org\/10.1016\/j.molimm.2008.04.025","journal-title":"Mol Immunol"},{"key":"2762_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1471-4159.1993.tb03568.x","volume":"61","author":"PE Fraser","year":"1993","unstructured":"Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA (1993) Alpha 1-antichymotrypsin binding to Alzheimer A\u03b2 peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 61:298\u2013305. https:\/\/doi.org\/10.1111\/j.1471-4159.1993.tb03568.x","journal-title":"J Neurochem"},{"key":"2762_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/00001756-199202000-00020","volume":"3","author":"PA Gollin","year":"1992","unstructured":"Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G (1992) \u03b11-Antitrypsin and \u03b11-antichymotrypsin are in the lesions of Alzheimer\u2019s disease. NeuroReport 3:201\u2013203. https:\/\/doi.org\/10.1097\/00001756-199202000-00020","journal-title":"NeuroReport"},{"key":"2762_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/jnr.10144","volume":"67","author":"YX Sun","year":"2002","unstructured":"Sun YX, Wright HT, Janciauskiene S (2002) \u03b11-antichymotrypsin\/Alzheimer\u2019s peptide A\u03b21-42 complex perturbs lipid metabolism and activates transcription factors PPAR\u03b3 and NF\u03baB in human neuroblastoma (Kelly) cells. J Neurosci Res 67:511\u2013522. https:\/\/doi.org\/10.1002\/jnr.10144","journal-title":"J Neurosci Res"},{"key":"2762_CR37","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/brain\/awl255","volume":"129","author":"J Padmanabhan","year":"2006","unstructured":"Padmanabhan J, Levy M, Dickson DW, Potter H (2006) Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer\u2019s disease brain, induces tau phosphorylation in neurons. Brain 129:3020\u20133034. https:\/\/doi.org\/10.1093\/brain\/awl255","journal-title":"Brain"},{"key":"2762_CR38","doi-asserted-by":"publisher","first-page":"15637","DOI":"10.1038\/s41598-017-15778-8","volume":"7","author":"S Vanni","year":"2017","unstructured":"Vanni S, Moda F, Zattoni M, Bistaffa E, De Cecco E, Rossi M et al (2017) Differential overexpression of SERPINA3 in human prion diseases. Sci Rep 7:15637. https:\/\/doi.org\/10.1038\/s41598-017-15778-8","journal-title":"Sci Rep"},{"key":"2762_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ana.10414","volume":"53","author":"ST DeKosky","year":"2003","unstructured":"DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL et al (2003) Plasma and cerebrospinal fluid \u03b11-antichymotrypsin levels in Alzheimer\u2019s disease: Correlation with cognitive impairment. Ann Neurol 53:81\u201390. https:\/\/doi.org\/10.1002\/ana.10414","journal-title":"Ann Neurol"},{"key":"2762_CR40","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1523\/JNEUROSCI.21-05-01444.2001","volume":"21","author":"LNGG Nilsson","year":"2001","unstructured":"Nilsson LNGG, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM et al (2001) \u03b1-1-Antichymotrypsin promotes \u03b2-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci 21:1444\u20131451. https:\/\/doi.org\/10.1523\/JNEUROSCI.21-05-01444.2001","journal-title":"J Neurosci"},{"key":"2762_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/606083","volume":"2013","author":"E Tyagi","year":"2013","unstructured":"Tyagi E, Fiorelli T, Norden M, Padmanabhan J (2013) Alpha 1-antichymotrypsin, an inflammatory protein overexpressed in the brains of patients with Alzheimer\u2019s disease, induces tau hyperphosphorylation through c-Jun N-terminal kinase activation. Int J Alzheimers Dis 2013:606083. https:\/\/doi.org\/10.1155\/2013\/606083","journal-title":"Int J Alzheimers Dis"},{"key":"2762_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0092-8674(88)90462-X","volume":"52","author":"CR Abraham","year":"1988","unstructured":"Abraham CR, Selkoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor \u03b11-antichymotrypsin in the brain amyloid deposits of Alzheimer\u2019s disease. Cell 52:487\u2013501. https:\/\/doi.org\/10.1016\/0092-8674(88)90462-X","journal-title":"Cell"},{"key":"2762_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0165-5728(98)00096-4","volume":"88","author":"F Licastro","year":"1998","unstructured":"Licastro F, Mallory M, Hansen LA, Masliah E (1998) Increased levels of \u03b1-1-antichymotrypsin in brains of patients with Alzheimer\u2019s disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 88:105\u2013110. https:\/\/doi.org\/10.1016\/S0165-5728(98)00096-4","journal-title":"J Neuroimmunol"},{"key":"2762_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/00002093-199509020-00009","volume":"9","author":"F Licastro","year":"1995","unstructured":"Licastro F, Parnetti L, Morini M, Davis L, Cucinotta D, Gaiti A et al (1995) Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis Assoc Disord 9:112\u2013118. https:\/\/doi.org\/10.1097\/00002093-199509020-00009","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2762_CR45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.410280414","volume":"28","author":"E Matsubara","year":"1990","unstructured":"Matsubara E, Hirai S, Amari M, Shoji M, Yamaguchi H, Okamoto K et al (1990) \u03b11-Antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 28:561\u2013567. https:\/\/doi.org\/10.1002\/ana.410280414","journal-title":"Ann Neurol"},{"key":"2762_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0197-4580(91)90042-i","volume":"12","author":"C Delamarche","year":"1991","unstructured":"Delamarche C, Berger F, Gallard L, Pouplard-Barthelaix A (1991) Aging and Alzheimer\u2019s disease: protease inhibitors in cerebrospinal fluid. Neurobiol Aging 12:71\u201374. https:\/\/doi.org\/10.1016\/0197-4580(91)90042-i","journal-title":"Neurobiol Aging"},{"key":"2762_CR47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/jnnp.54.5.469","volume":"54","author":"A Furby","year":"1991","unstructured":"Furby A, Leys D, Delacourte A, Buee L, Soetaert G, Petit H (1991) Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer\u2019s disease? J Neurol Neurosurg Psychiatry 54:469. https:\/\/doi.org\/10.1136\/jnnp.54.5.469","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2762_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0197-4580(94)90026-4","volume":"15","author":"T Pirttila","year":"1994","unstructured":"Pirttila T, Mehta PD, Frey H, Wisniewski HM (1994) \u03b11-Antichymotrypsin and IL-1\u03b2 are not increased in CSF or serum in Alzheimer\u2019s disease. Neurobiol Aging 15:313\u2013317. https:\/\/doi.org\/10.1016\/0197-4580(94)90026-4","journal-title":"Neurobiol Aging"},{"key":"2762_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00002093-199809000-00016","volume":"12","author":"AS Lanzrein","year":"1998","unstructured":"Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD (1998) Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: Interleukin-1\u03b2, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-\u03b1, the soluble tumor necrosis factor receptors I and I. Alzheimer Dis Assoc Disord 12:215\u2013227. https:\/\/doi.org\/10.1097\/00002093-199809000-00016","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2762_CR50","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0006-3223(95)00426-2","volume":"39","author":"BA Lawlor","year":"1996","unstructured":"Lawlor BA, Swanwick GRJ, Feighery C, Walsh JB, Coakley D (1996) Acute phase reactants in Alzheimer\u2019s disease. Biol Psychiatry 39:1051\u20131052. https:\/\/doi.org\/10.1016\/0006-3223(95)00426-2","journal-title":"Biol Psychiatry"},{"key":"2762_CR51","first-page":"707","volume":"317","author":"E Matsubara","year":"1989","unstructured":"Matsubara E, Amari M, Shoji M, Harigaya Y, Yamaguchi H, Okamoto K et al (1989) Serum concentration of alpha 1-antichymotrypsin is elevated in patients with senile dementia of the Alzheimer type. Prog Clin Biol Res 317:707\u2013714","journal-title":"Prog Clin Biol Res"},{"key":"2762_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410320211","volume":"32","author":"K Brugge","year":"1992","unstructured":"Brugge K, Katzman R, Hill LR, Hansen LA, Saitoh T (1992) Serological \u03b11-antichymotrypsin in Down\u2019s syndrome and Alzheimer\u2019s disease. Ann Neurol 32:193\u2013197. https:\/\/doi.org\/10.1002\/ana.410320211","journal-title":"Ann Neurol"},{"key":"2762_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000106917","volume":"6","author":"LD Altstiel","year":"1995","unstructured":"Altstiel LD, Lawlor B, Mohs R, Schmeidler J, Dalton A, Mehta P et al (1995) Elevated alpha1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer\u2019s disease patients. Dement Geriatr Cogn Disord 6:17\u201320. https:\/\/doi.org\/10.1159\/000106917","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2762_CR54","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/0197-4580(95)00056-k","volume":"16","author":"J Lieberman","year":"1995","unstructured":"Lieberman J, Schleissner L, Tachiki KH, Kling AS (1995) Serum \u03b11-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging 16:747\u2013753. https:\/\/doi.org\/10.1016\/0197-4580(95)00056-k","journal-title":"Neurobiol Aging"},{"key":"2762_CR55","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1212\/01.wnl.0000271077.82508.a0","volume":"69","author":"HM Nielsen","year":"2007","unstructured":"Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J et al (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69:1569\u20131579. https:\/\/doi.org\/10.1212\/01.wnl.0000271077.82508.a0","journal-title":"Neurology"},{"key":"2762_CR56","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.2174\/138161208786264151","volume":"14","author":"E Porcellini","year":"2008","unstructured":"Porcellini E, Davis E, Chiappelli M, Ianni E, Di Stefano G, Forti P et al (2008) Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimers disease: a potential therapeutic target. Curr Pharm Des 14:2659\u20132664. https:\/\/doi.org\/10.2174\/138161208786264151","journal-title":"Curr Pharm Des"},{"issue":"97\u2013102","key":"2762_CR57","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0165-5728(99)00226-X","volume":"103","author":"F Licastro","year":"2000","unstructured":"Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C et al (2000) Increased plasma levels of interleukin-1, interleukin-6 and \u03b1-1-antichymotrypsin in patients with Alzheimer\u2019s disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103(97\u2013102):738. https:\/\/doi.org\/10.1016\/S0165-5728(99)00226-X","journal-title":"J Neuroimmunol"},{"key":"2762_CR58","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3233\/JAD-140111","volume":"41","author":"Y-HH Shih","year":"2014","unstructured":"Shih Y-HH, Tsai K-JJ, Lee C-WW, Shiesh S-CC, Chen W-TT, Pai M-CC et al (2014) Apolipoprotein C-III is an amyloid-\u03b2-binding protein and an early marker for Alzheimer\u2019s disease. J Alzheimers Dis 41:855\u2013865. https:\/\/doi.org\/10.3233\/JAD-140111","journal-title":"J Alzheimers Dis"},{"key":"2762_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000323417","volume":"1","author":"A \u00d6hrfelt","year":"2011","unstructured":"\u00d6hrfelt A, Andreasson U, Simon A, Zetterberg H, Edman \u00c5, Potter W et al (2011) Screening for new biomarkers for subcortical vascular dementia and Alzheimer\u2019s disease. Dement Geriatr Cogn Dis Extra 1:31\u201342. https:\/\/doi.org\/10.1159\/000323417","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"2762_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034078","volume":"7","author":"S Fei","year":"2012","unstructured":"Fei S, Anne P, John C, Nicole AK, Wei W, Barbara C et al (2012) Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS ONE 7:e34078. https:\/\/doi.org\/10.1371\/journal.pone.0034078","journal-title":"PLoS ONE"},{"key":"2762_CR61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1477-5956-12-5","volume":"12","author":"F Song","year":"2014","unstructured":"Song F, Poljak A, Kochan NA, Raftery M, Brodaty H, Smythe GA et al (2014) Plasma protein profiling of mild cognitive impairment and Alzheimer\u2019s disease using iTRAQ quantitative proteomics. Proteome Sci 12:5. https:\/\/doi.org\/10.1186\/1477-5956-12-5","journal-title":"Proteome Sci"},{"key":"2762_CR62","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.celrep.2019.07.060","volume":"28","author":"T Wu","year":"2019","unstructured":"Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S et al (2019) Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep 28:2111-2123.e6. https:\/\/doi.org\/10.1016\/j.celrep.2019.07.060","journal-title":"Cell Rep"},{"key":"2762_CR63","doi-asserted-by":"publisher","unstructured":"Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, et al (2017) Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice. Sci Transl Med 9:eaaf6295. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6295","DOI":"10.1126\/scitranslmed.aaf6295"},{"key":"2762_CR64","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.jalz.2018.07.223","volume":"14","author":"KL Rasmussen","year":"2018","unstructured":"Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R, Nielsen SF (2018) An updated Alzheimer hypothesis: complement C3 and risk of Alzheimer\u2019s disease\u2014a cohort study of 95,442 individuals. Alzheimer\u2019s Dement 14:1589\u20131601. https:\/\/doi.org\/10.1016\/j.jalz.2018.07.223","journal-title":"Alzheimer\u2019s Dement"},{"key":"2762_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1742-2094-5-9","volume":"5","author":"DA Loeffler","year":"2008","unstructured":"Loeffler DA, Camp DM, Bennett DA (2008) Plaque complement activation and cognitive loss in Alzheimer\u2019s disease. J Neuroinflammation 5:9. https:\/\/doi.org\/10.1186\/1742-2094-5-9","journal-title":"J Neuroinflammation"},{"key":"2762_CR66","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S0002-9440(10)65340-0","volume":"154","author":"K Yasojima","year":"1999","unstructured":"Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Up-regulated production and activation of the complement system in Alzheimer\u2019s disease brain. Am J Pathol 154:927\u2013936. https:\/\/doi.org\/10.1016\/S0002-9440(10)65340-0","journal-title":"Am J Pathol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-022-02762-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-022-02762-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-022-02762-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:11:42Z","timestamp":1650352302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-022-02762-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2762"],"URL":"https:\/\/doi.org\/10.1007\/s12035-022-02762-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-787466\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-787466\/v2","asserted-by":"object"}]},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"2 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sample collection as well as their use in research was approved by the ethics committee for health of the Central Regional Administration of Coimbra (CES da ARS Centro, protocol No. 012804\u201304.04.2012, Portuguese National Committee for Data Protection (Authorization N\u00ba 369\/2012) for the pcb-cohort, and by the ethics committee of the University Goettingen (9\/2\/16) for the UMG-cohort. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}